Paul Clarke

Paul Clarke is an Honorary Professor at Norwich Medical School, University of East Anglia, and a Consultant Neonatologist at Norfolk & Norwich University Hospitals NHS Foundation Trust, a role he has held since January 4, 2005. His work bridges clinical practice and academic research in neonatal medicine.

Research Interests: His primary research areas include neonatal pharmacology, vaccine trials in preterm infants, infection prevention in neonatal intensive care, respiratory support strategies, and therapeutic hypothermia. He employs clinical trials, national surveys, and pharmacokinetic modeling to advance neonatal care.

Publication Trends: His recent work (2024–2025) reflects a strong focus on clinical trials and national practice assessments, particularly in neonatal infection control, immunization, and respiratory interventions. These studies often involve multi-center collaborations and are published in leading pediatric journals such as Archives of Disease in Childhood.

Scientific Engagement:

• Principal or key investigator in major trials including the ARCTIC feasibility trial, RENOIR study, and meningococcal B vaccine trials.
• Media and policy impact through coverage of innovative studies like the RHYME mRNA vaccine trial and the first neonatal cannabinoid drug trial in the UK.

Advising and Grants: While specific students or grant awards are not listed, his leadership in funded clinical trials (e.g., ARCTIC, RHYME) indicates active grant acquisition and mentorship of junior researchers and clinicians. His collaborations span institutions in the UK and Europe, reflecting a broad research network.

Labs and Teams: He is embedded within the neonatal research team at Norfolk & Norwich University Hospitals and collaborates with academic groups at UEA and beyond. He contributes to national neonatal research initiatives and is involved in shaping clinical guidelines through evidence generation.